Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York. Show more
19 Vestry Street, New York, NY, 10013, United States
Market Cap
731M
52 Wk Range
$23.18 - $123.75
Previous Close
$74.50
Open
$73.64
Volume
711,644
Day Range
$67.04 - $73.64
Enterprise Value
586M
Cash
309.7M
Avg Qtr Burn
-9.246M
Insider Ownership
11.53%
Institutional Own.
92.81%
Qtr Updated
03/31/26
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
BMB-101 Details Epilepsy, Developmental and Epileptic Encephalopathy (DEE), Absence Seizures (AS) | Phase 2 Update | |
BMB-101 Details Prader-Willi Syndrome (PWS) | Phase 2a Update | |
BMB-105 Details Prader-Willi Syndrome (PWS) | Phase 1 Data readout |